Physician profile
Clara Ampadu
NPI 1578096806
$6,113.31
in general payments reported to CMS, 2019-2025
48 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $328 · 2022: $1,464 · 2023: $1,508 · 2024: $1,368 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,210 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,210.26 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $736.70 | 2022-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $623.74 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lilly USA, LLC | $597.34 | 2022-2025 | Trulicity, Mounjaro, Zepbound |
| Ucb, INC. | $404.10 | 2021-2024 | Briviact, Nayzilam |
| Janssen Pharmaceuticals, INC | $312.68 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Otsuka America Pharmaceutical, INC. | $312.43 | 2023-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Lundbeck LLC | $307.99 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $302.44 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $210.26 | 2021-2024 | |
| Neurelis, INC. | $191.79 | 2023-2025 | Valtoco |
| Sumitomo Pharma America, INC. | $184.09 | 2023-2024 | Aptiom |
| Astrazeneca Pharmaceuticals LP | $146.98 | 2022-2025 | Farxiga, Lokelma, Fasenra |
| Novo Nordisk INC | $137.02 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Axsome Therapeutics, INC. | $131.04 | 2023-2025 | Auvelity |
| Sanofi-Aventis U.S. LLC | $117.14 | 2024-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clara Ampadu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.